{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T20:29:14Z","timestamp":1782937754996,"version":"3.54.5"},"reference-count":78,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Endosc Ultrasound"],"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:sec>\n            <jats:title>Background and Objective<\/jats:title>\n            <jats:p>Pancreatic ductal adenocarcinoma (PDAC) is among the most lethal cancers, with a 5-year survival rate of around 9%. Only 20% are candidates for surgery. Most unresectable patients undergo EUS-guided fine-needle biopsy (EUS-FNB) for diagnosis. Identification of targetable mutations using next-generation sequencing (NGS) is increasingly requested. Data on feasibility of EUS-FNB for NGS and knowledge regarding mutational profile of unresectable PDAC are scarce. We evaluated the \u201ctechnical yield\u201d of EUS-FNB for NGS in unresectable PDAC: relative fraction of diagnostic EUS-FNBs meeting technical criteria. We also investigated the \u201cmolecular yield\u201d: relative fraction of EUS-FNBs included in NGS containing sufficient DNA for detection of at least one mutation. Furthermore, we determined the relative frequency of cancer-associated mutations in unresectable PDAC.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>Formalin-fixed and paraffin-embedded EUS-FNBs diagnostic of unresectable PDAC and fulfilling these criteria were included (<jats:italic toggle=\"yes\">n<\/jats:italic> = 105): minimum 3-mm<jats:sup>2<\/jats:sup> tissue, minimum of 2-mm<jats:sup>2<\/jats:sup> tumor area, and minimum 20% relative tumor area. NGS was performed using Ion GeneStudio S5 Prime System and Oncomine\u2122 Comprehensive Assay v.3 including 161 cancer-related genes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Technical yield was 48% (105\/219) and molecular yield was 98% (103\/105). Most frequently mutated genes were <jats:italic toggle=\"yes\">KRAS<\/jats:italic> (89.3%) and <jats:italic toggle=\"yes\">TP53<\/jats:italic> (69.9%), followed by <jats:italic toggle=\"yes\">CDKN2A<\/jats:italic> (24.3%), <jats:italic toggle=\"yes\">ARID1A<\/jats:italic> (9.7%), <jats:italic toggle=\"yes\">SMAD4<\/jats:italic> (7.8%), <jats:italic toggle=\"yes\">TSC2<\/jats:italic> (7.8%), and <jats:italic toggle=\"yes\">CCND3<\/jats:italic> (6.8%).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>EUS-FNB for NGS of unresectable PDAC is feasible. Our technical criteria for NGS, using leftovers in formalin-fixed and paraffin-embedded blocks after routine pathology diagnosis, were met by around half of EUS-FNBs. Almost all EUS-FNBs fulfilling the technical criteria yielded a successful NGS analysis.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/eus.0000000000000072","type":"journal-article","created":{"date-parts":[[2024,7,3]],"date-time":"2024-07-03T00:02:07Z","timestamp":1719964927000},"page":"154-164","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":6,"title":["Mutational profiling of 103 unresectable pancreatic ductal adenocarcinomas using EUS-guided fine-needle biopsy"],"prefix":"10.1097","volume":"13","author":[{"given":"Julie","family":"Buchberg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"de Stricker","sequence":"additional","affiliation":[{"name":"Department of Pathology, Odense University Hospital, Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Per","family":"Pfeiffer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael Bau","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f6nke","family":"Detlefsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,7,3]]},"reference":[{"key":"bib1-20250826","article-title":"World Pancreatic Cancer Day 2022","year":"2022","journal-title":"World Pancreatic Cancer Day"},{"key":"bib2-20250826","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.canep.2018.04.011","article-title":"Analysis of incidence, mortality and survival for pancreatic and biliary tract cancers across Europe, with assessment of influence of revised European age standardisation on estimates","volume":"55","year":"2018","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"bib3-20250826","first-page":"7","article-title":"Cancer statistics, 2021","volume":"71","year":"2021","journal-title":"CA Cancer J Clin"},{"issue":"10","key":"bib4-20250826","doi-asserted-by":"crossref","first-page":"2674","DOI":"10.1002\/cncr.26553","article-title":"Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent","volume":"118","year":"2012","journal-title":"Cancer"},{"issue":"1","key":"bib5-20250826","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1186\/s13045-020-00958-3","article-title":"Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma","volume":"13","year":"2020","journal-title":"J Hematol Oncol"},{"issue":"11","key":"bib6-20250826","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1038\/s41401-020-00584-2","article-title":"Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications","volume":"42","year":"2021","journal-title":"Acta Pharmacol Sin"},{"issue":"13","key":"bib7-20250826","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6","key":"bib8-20250826","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1097\/MPA.0000000000001324","article-title":"Next-generation sequencing in pancreatic cancer","volume":"48","year":"2019","journal-title":"Pancreas"},{"issue":"11","key":"bib9-20250826","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1016\/j.cgh.2022.10.014","article-title":"Routine molecular profiling in both resectable and unresectable pancreatic adenocarcinoma: relevance of cytologic samples","volume":"21","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"bib10-20250826","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.3390\/cancers13112791","article-title":"Accurate prognosis prediction of pancreatic ductal adenocarcinoma using integrated clinico-genomic data of endoscopic ultrasound\u2013guided fine needle biopsy","volume":"13","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"2","key":"bib11-20250826","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.gie.2011.08.049","article-title":"EUS-guided FNA for diagnosis of solid pancreatic neoplasms: a meta-analysis","volume":"75","year":"2012","journal-title":"Gastrointest Endosc"},{"issue":"3","key":"bib12-20250826","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1111\/cyt.12071","article-title":"The presence of a cytopathologist increases the diagnostic accuracy of endoscopic ultrasound\u2013guided fine needle aspiration cytology for pancreatic adenocarcinoma: a meta-analysis","volume":"24","year":"2013","journal-title":"Cytopathology"},{"issue":"5","key":"bib13-20250826","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1111\/jgh.14540","article-title":"Comparison of endoscopic ultrasound tissue acquisition methods for genomic analysis of pancreatic cancer","volume":"34","year":"2019","journal-title":"J Gastroenterol Hepatol"},{"issue":"4","key":"bib14-20250826","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1055\/a-1223-2171","article-title":"Comparison of endoscopic ultrasound\u2013guided fine-needle biopsy versus fine-needle aspiration for genomic profiling and DNA yield in pancreatic cancer: a randomized crossover trial","volume":"53","year":"2021","journal-title":"Endoscopy"},{"issue":"4","key":"bib15-20250826","doi-asserted-by":"crossref","first-page":"306","DOI":"10.4103\/EUS-D-21-00180","article-title":"Accuracy and clinical outcomes of pancreatic EUS-guided fine-needle biopsy in a consecutive series of 852 specimens","volume":"11","year":"2022","journal-title":"Endosc Ultrasound"},{"issue":"2","key":"bib16-20250826","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.pan.2019.12.002","article-title":"Endoscopic ultrasound may be used to deliver gene expression signatures using digital mRNA detection methods to immunophenotype pancreatic ductal adenocarcinoma to facilitate personalized immunotherapy","volume":"20","year":"2020","journal-title":"Pancreatology"},{"issue":"12","key":"bib17-20250826","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1136\/gutjnl-2017-315154","article-title":"EUS-guided fine needle biopsy of pancreatic masses can yield true histology","volume":"67","year":"2018","journal-title":"Gut"},{"issue":"3","key":"bib18-20250826","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/j.pan.2021.01.025","article-title":"Gene expression profiling of morphologic subtypes of pancreatic ductal adenocarcinoma using surgical and EUS-FNB specimens","volume":"21","year":"2021","journal-title":"Pancreatology"},{"issue":"25","key":"bib19-20250826","first-page":"V01220044","article-title":"Digital pathology","volume":"184","year":"2022","journal-title":"Ugeskr Laeger"},{"issue":"2","key":"bib20-20250826","doi-asserted-by":"crossref","first-page":"E242","DOI":"10.1055\/s-0043-124078","article-title":"Prospective evaluation of EUS-guided fine needle biopsy in pancreatic mass lesions","volume":"6","year":"2018","journal-title":"Endosc Int Open"},{"issue":"3","key":"bib21-20250826","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MPA.0b013e3182142fd2","article-title":"International consensus diagnostic criteria for autoimmune pancreatitis: guidelines of the International Association of Pancreatology","volume":"40","year":"2011","journal-title":"Pancreas"},{"issue":"5","key":"bib22-20250826","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/gim.2015.30","article-title":"Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology","volume":"17","year":"2015","journal-title":"Genet Med"},{"issue":"3","key":"bib23-20250826","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1093\/oncolo\/oyab053","article-title":"Homologous recombination deficiency: concepts, definitions, and assays","volume":"27","year":"2022","journal-title":"Oncologist"},{"issue":"23","key":"bib24-20250826","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.20.03238","article-title":"Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis","volume":"39","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"bib25-20250826","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/bjc.1991.467","article-title":"Abnormalities of the p53 tumour suppressor gene in human pancreatic cancer","volume":"64","year":"1991","journal-title":"Br J Cancer"},{"issue":"11","key":"bib26-20250826","first-page":"3025","article-title":"p53 Mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions","volume":"54","year":"1994","journal-title":"Cancer Res"},{"issue":"17","key":"bib27-20250826","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1002\/cncr.33038","article-title":"Alterations in driver genes are predictive of survival in patients with resected pancreatic ductal adenocarcinoma","volume":"126","year":"2020","journal-title":"Cancer"},{"issue":"6","key":"bib28-20250826","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrclinonc.2013.66","article-title":"Advanced-stage pancreatic cancer: therapy options","volume":"10","year":"2013","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"bib29-20250826","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/eus.0000000000000007","article-title":"Tissue amount and diagnostic yield of a novel Franseen EUS-FNB and a standard EUS-FNA needle\u2014a randomized controlled study in solid pancreatic lesions","volume":"12","year":"2023","journal-title":"Endosc Ultrasound"},{"issue":"4","key":"bib30-20250826","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1002\/cncy.22533","article-title":"Adequacy evaluation and use of pancreatic adenocarcinoma specimens for next-generation sequencing acquired by endoscopic ultrasound\u2013guided FNA and FNB","volume":"130","year":"2022","journal-title":"Cancer Cytopathol"},{"issue":"3","key":"bib31-20250826","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1038\/s43018-022-00349-2","article-title":"Translational advances in pancreatic ductal adenocarcinoma therapy","volume":"3","year":"2022","journal-title":"Nat Cancer"},{"key":"bib32-20250826","doi-asserted-by":"crossref","first-page":"682872","DOI":"10.3389\/fonc.2021.682872","article-title":"Molecular and phenotypic profiling for precision medicine in pancreatic cancer: current advances and future perspectives","volume":"11","year":"2021","journal-title":"Front Oncol"},{"issue":"6","key":"bib33-20250826","doi-asserted-by":"crossref","first-page":"152985","DOI":"10.1016\/j.prp.2020.152985","article-title":"Frequency of mismatch repair deficiency in pancreatic ductal adenocarcinoma","volume":"216","year":"2020","journal-title":"Pathol Res Pract"},{"issue":"4","key":"bib34-20250826","doi-asserted-by":"crossref","first-page":"427","DOI":"10.3390\/diagnostics14040427","article-title":"EUS-FNA versus EUS-FNB in pancreatic solid lesions \u2264 15 mm","volume":"14","year":"2024","journal-title":"Diagnostics (Basel)"},{"issue":"1","key":"bib35-20250826","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1186\/s13046-020-01732-6","article-title":"KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities","volume":"39","year":"2020","journal-title":"J Exp Clin Cancer Res"},{"issue":"9","key":"bib36-20250826","doi-asserted-by":"crossref","first-page":"a031435","DOI":"10.1101\/cshperspect.a031435","article-title":"KRAS: the critical driver and therapeutic target for pancreatic cancer","volume":"8","year":"2018","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"8","key":"bib37-20250826","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41573-020-0068-6","article-title":"RAS-targeted therapies: is the undruggable drugged?","volume":"19","year":"2020","journal-title":"Nat Rev Drug Discov"},{"key":"bib38-20250826","doi-asserted-by":"crossref","first-page":"6744","DOI":"10.1038\/ncomms7744","article-title":"Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets","volume":"6","year":"2015","journal-title":"Nat Commun"},{"issue":"12","key":"bib39-20250826","doi-asserted-by":"crossref","first-page":"2704","DOI":"10.1158\/1078-0432.CCR-21-3581","article-title":"Molecular characterization of KRAS wild-type tumors in patients with pancreatic adenocarcinoma","volume":"28","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"15_suppl","key":"bib40-20250826","doi-asserted-by":"crossref","first-page":"4641","DOI":"10.1200\/JCO.2020.38.15_suppl.4641","article-title":"Comprehensive analysis of KRAS variants in patients (pts) with pancreatic cancer (PDAC): clinical\/molecular correlations and real-world outcomes across standard therapies","volume":"38","year":"2020","journal-title":"J Clin Oncol"},{"issue":"4","key":"bib41-20250826","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1002\/cam4.3723","article-title":"Clinical significance of genetic alterations in endoscopically obtained pancreatic cancer specimens","volume":"10","year":"2021","journal-title":"Cancer Med"},{"issue":"4","key":"bib42-20250826","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1177\/1947601911408889","article-title":"Mutations in the p53 tumor suppressor gene: important milestones at the various steps of tumorigenesis","volume":"2","year":"2011","journal-title":"Genes Cancer"},{"issue":"5170","key":"bib43-20250826","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1126\/science.8023157","article-title":"Crystal structure of a p53 tumor suppressor\u2013DNA complex: understanding tumorigenic mutations","volume":"265","year":"1994","journal-title":"Science"},{"issue":"7540","key":"bib44-20250826","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/nature14169","article-title":"Whole genomes redefine the mutational landscape of pancreatic cancer","volume":"518","year":"2015","journal-title":"Nature"},{"issue":"3","key":"bib45-20250826","doi-asserted-by":"crossref","first-page":"850","DOI":"10.3390\/cancers14030850","article-title":"Genetic alterations predict long-term survival in ductal adenocarcinoma of the pancreatic head","volume":"14","year":"2022","journal-title":"Cancers (Basel)"},{"key":"bib46-20250826","doi-asserted-by":"crossref","first-page":"7686","DOI":"10.1038\/ncomms8686","article-title":"Clinical implications of genomic alterations in the tumour and circulation of pancreatic cancer patients","volume":"6","year":"2015","journal-title":"Nat Commun"},{"issue":"5247","key":"bib48-20250826","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1126\/science.271.5247.350","article-title":"DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1","volume":"271","year":"1996","journal-title":"Science"},{"issue":"3","key":"bib49-20250826","first-page":"490","article-title":"Homozygous deletion map at 18q21.1 in pancreatic cancer","volume":"56","year":"1996","journal-title":"Cancer Res"},{"issue":"9","key":"bib50-20250826","first-page":"1731","article-title":"Tumor-suppressive pathways in pancreatic carcinoma","volume":"57","year":"1997","journal-title":"Cancer Res"},{"issue":"8","key":"bib51-20250826","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1053\/j.gastro.2019.02.037","article-title":"Real-time targeted genome profile analysis of pancreatic ductal adenocarcinomas identifies genetic alterations that might be targeted with existing drugs or used as biomarkers","volume":"156","year":"2019","journal-title":"Gastroenterology"},{"issue":"8","key":"bib52-20250826","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1158\/2159-8290.CD-17-0151","article-title":"AACR Project GENIE: powering precision medicine through an international consortium","volume":"7","year":"2017","journal-title":"Cancer Discov"},{"issue":"28","key":"bib53-20250826","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1200\/JCO.2014.59.7401","article-title":"Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma","volume":"33","year":"2015","journal-title":"J Clin Oncol"},{"issue":"1","key":"bib54-20250826","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1038\/s41436-018-0009-5","article-title":"Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer","volume":"21","year":"2019","journal-title":"Genet Med"},{"issue":"4","key":"bib55-20250826","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","year":"2019","journal-title":"N Engl J Med"},{"issue":"30","key":"bib56-20250826","doi-asserted-by":"crossref","first-page":"3382","DOI":"10.1200\/JCO.2017.72.3502","article-title":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma","volume":"35","year":"2017","journal-title":"J Clin Oncol"},{"issue":"23","key":"bib57-20250826","doi-asserted-by":"crossref","first-page":"4393","DOI":"10.1002\/cncr.33812","article-title":"Pancreas cancer and BRCA: a critical subset of patients with improving therapeutic outcomes","volume":"127","year":"2021","journal-title":"Cancer"},{"issue":"10","key":"bib58-20250826","doi-asserted-by":"crossref","first-page":"T57","DOI":"10.1530\/ERC-16-0269","article-title":"Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers","volume":"23","year":"2016","journal-title":"Endocr Relat Cancer"},{"key":"bib59-20250826","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.2147\/CMAR.S211151","article-title":"BRCA mutations in pancreas cancer: spectrum, current management, challenges and future prospects","volume":"12","year":"2020","journal-title":"Cancer Manag Res"},{"issue":"9","key":"bib60-20250826","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1136\/jmg.2004.028829","article-title":"Cancer risks in BRCA2 families: estimates for sites other than breast and ovary","volume":"42","year":"2005","journal-title":"J Med Genet"},{"issue":"4","key":"bib61-20250826","doi-asserted-by":"crossref","first-page":"897","DOI":"10.3390\/cancers14040897","article-title":"Precision medicine for BRCA\/PALB2-mutated pancreatic cancer and emerging strategies to improve therapeutic responses to PARP inhibition","volume":"14","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"8","key":"bib62-20250826","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1158\/2159-8290.CD-22-0412","article-title":"Spectrum of response to platinum and PARP inhibitors in germline BRCA-associated pancreatic cancer in the clinical and preclinical setting","volume":"13","year":"2023","journal-title":"Cancer Discov"},{"issue":"1","key":"bib63-20250826","doi-asserted-by":"crossref","first-page":"108","DOI":"10.3390\/genes11010108","article-title":"ATM serine\/threonine kinase and its role in pancreatic risk","volume":"11","year":"2020","journal-title":"Genes (Basel)"},{"issue":"13","key":"bib64-20250826","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","article-title":"Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection","volume":"26","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"7","key":"bib65-20250826","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1158\/1078-0432.CCR-13-1239","article-title":"Having pancreatic cancer with tumoral loss of ATM and normal TP53 protein expression is associated with a poorer prognosis","volume":"20","year":"2014","journal-title":"Clin Cancer Res"},{"issue":"2","key":"bib66-20250826","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1097\/MPA.0000000000000248","article-title":"Ataxia-telangiectasia\u2013mutated protein kinase levels stratify patients with pancreatic adenocarcinoma into prognostic subgroups with loss being a strong indicator of poor survival","volume":"44","year":"2015","journal-title":"Pancreas"},{"issue":"6","key":"bib67-20250826","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1038\/bjc.2017.19","article-title":"Overall survival and clinical characteristics of BRCA mutation carriers with stage I\/II pancreatic cancer","volume":"116","year":"2017","journal-title":"Br J Cancer"},{"issue":"6","key":"bib68-20250826","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1053\/j.gastro.2019.01.254","article-title":"Prevalence of germline mutations associated with cancer risk in patients with intraductal papillary mucinous neoplasms","volume":"156","year":"2019","journal-title":"Gastroenterology"},{"issue":"3","key":"bib69-20250826","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1053\/j.gastro.2009.06.055","article-title":"Analysis of the gene coding for the BRCA2-interacting protein PALB2 in familial and sporadic pancreatic cancer","volume":"137","year":"2009","journal-title":"Gastroenterology"},{"issue":"2","key":"bib70-20250826","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10689-011-9426-1","article-title":"PALB2 mutations in familial breast and pancreatic cancer","volume":"10","year":"2011","journal-title":"Fam Cancer"},{"key":"bib71-20250826","first-page":"PO.17.00286","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","volume":"2018","year":"2018","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"bib72-20250826","doi-asserted-by":"crossref","first-page":"e000578","DOI":"10.1136\/esmoopen-2019-000578","article-title":"Efficacy of platinum-based chemotherapy and prognosis of patients with pancreatic cancer with homologous recombination deficiency: comparative analysis of published clinical studies","volume":"5","year":"2020","journal-title":"ESMO Open"},{"issue":"1","key":"bib73-20250826","first-page":"1","article-title":"A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma","volume":"9","year":"2017","journal-title":"J Gastrointest Oncol"},{"key":"bib74-20250826","doi-asserted-by":"crossref","first-page":"113497","DOI":"10.1016\/j.ejca.2023.113497","article-title":"Precision medicine for KRAS wild-type pancreatic adenocarcinomas","volume":"197","year":"2024","journal-title":"Eur J Cancer"},{"issue":"2","key":"bib75-20250826","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11523-023-00950-0","article-title":"Precision oncology in pancreatic cancer: experiences and challenges of the CCCMunich (LMU) Molecular Tumor Board","volume":"18","year":"2023","journal-title":"Target Oncol"},{"issue":"5","key":"bib76-20250826","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1007\/s00432-022-04165-0","article-title":"Lessons learned: the first consecutive 1000 patients of the CCCMunichLMU Molecular Tumor Board","volume":"149","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"bib77-20250826","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1136\/jclinpath-2019-205912","article-title":"Mutational profiling and immunohistochemical analysis of a surgical series of ampullary carcinomas","volume":"72","year":"2019","journal-title":"J Clin Pathol"},{"issue":"8","key":"bib78-20250826","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1038\/modpathol.2015.57","article-title":"Sequencing of 279 cancer genes in ampullary carcinoma reveals trends relating to histologic subtypes and frequent amplification and overexpression of ERBB2 (HER2)","volume":"28","year":"2015","journal-title":"Mod Pathol"},{"issue":"11","key":"bib79-20250826","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1097\/PAS.0b013e31826399d8","article-title":"Ampullary region carcinomas: definition and site specific classification with delineation of four clinicopathologically and prognostically distinct subsets in an analysis of 249 cases","volume":"36","year":"2012","journal-title":"Am J Surg Pathol"}],"container-title":["Endoscopic Ultrasound"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/eus.0000000000000072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,26]],"date-time":"2025-08-26T18:01:26Z","timestamp":1756231286000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/eus.0000000000000072"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":78,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/eus.0000000000000072","relation":{},"ISSN":["2226-7190","2303-9027"],"issn-type":[{"value":"2226-7190","type":"electronic"},{"value":"2303-9027","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}